

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

Claims 1-3 (Canceled)


Claim 4 (Currently Amended): A method for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation selected from Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, and cerebral hemorrhage with amyloidosis, said method comprising administering an effective amount of according to claim 2 wherein the inhibitor is 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide; or a pharmaceutically acceptable salt thereof.

Claim 5 (Currently Amended): A method according to claim [[2]] 4 wherein a daily dose of 10 to 800 mg of a compound is administered to an adult human.

Claim 6 (Canceled)

Claim 7 (Currently Amended): A method according to claim [[2]] 4 wherein the disease to be treated is Alzheimer's disease.

Claim 8 (Currently Amended): A method of treating mammals suffering from neurological and vascular disorders related to beta-amyloid generation and/or aggregation selected from Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, and cerebral hemorrhage with amyloidosis which comprises administering to a said mammal in need of such treatment a pharmaceutical composition comprising
(a) a dose, effective against said neurological and vascular disorders related to beta-amyloid generation and/or aggregation, of 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide having the formula I



(I);

or a pharmaceutically acceptable salt thereof and

(b) a therapeutically effective amount of a second drug selected from drugs used to treat neurological and vascular disorders related to beta-amyloid generation and/or aggregation.

Claims 9-10 (canceled)